Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9399 Crown Crest Blvd
Ste 220
Parker, CO 80138Phone+1 303-805-1855Fax+1 303-805-4421
Summary
- Tyler Chan, MD, FACS is a board-certified general surgeon and endocrine surgeon. He specializes in thyroid, parathyroid, and adrenal surgery. Dr. Chan earned his B.A. at the University of California, Berkeley and his M.D. at the University of Sydney. Dr. Chan completed his surgical training at Drexel University College of Medicine in Philadelphia, followed by an endocrine surgery fellowship at Weill Cornell Medical College in New York. His research has been published in Surgery and the Journal of the American College of Surgeons.
Dr. Chan grew up in Oregon, and he moved his family to Colorado so his kids could grow up with the outdoors like he did.
Education & Training
- Drexel University College of Medicine/Hahnemann University HospitalResidency, Surgery, 2011 - 2016
- University of Sydney Faculty of MedicineClass of 2010
- University of California, BerkeleyBachelor of Arts, 1999 - 2003
- Weill Cornell MedicineEndocrine Surgery
Certifications & Licensure
- CO State Medical License 2017 - 2025
- CA State Medical License 2017 - 2023
- NY State Medical License 2016 - 2018
- PA State Medical License 2011 - 2016
- American Board of Surgery Surgery
Publications & Presentations
PubMed
- 83 citationsNutrition impacts the prevalence of peripheral arterial disease in the United States.John S. Lane, Cheryl P. Magno, Karen T. Lane, Tyler Chan, David B. Hoyt
Journal of Vascular Surgery. 2008-10-01 - 33 citationsParathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival.Brendan M. Finnerty, Tyler W. Chan, Gregory Jones, Tarek Khader, Maureen D. Moore
Surgery. 2019-01-01 - 51 citationsJAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.Sizhi P. Gao, Qing Chang, Ninghui Mao, Laura Daly, Robert Vogel
Science Signaling. 2016-03-29
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: